Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sublivac
- Development stage
- Unknown
- Lead developer
- HAL Allergy
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Sublivac is a sublingual immunotherapy (SLIT) product developed by HAL Allergy BV for the treatment of IgE-mediated allergic disorders, including allergic rhinitis and rhinoconjunctivitis. It is formulated as a liquid allergen extract administered as drops under the tongue, containing standardized allergens derived from sources such as birch pollen, tree pollen mixtures (birch, hazel, alder), and house dust mites. The mechanism of action involves the induction of immunological tolerance to specific causative allergens, thereby modulating the allergic immune response and reducing symptoms over time. Sublivac is available in several specific formulations, such as SUBLIVAC FIX Birch and SUBLIVAC FIX Mite mixture, and has been evaluated in Phase 4 clinical trials to optimize dosing schedules, including the assessment of accelerated rush-in phases to improve patient convenience and adherence.
- Brand names
- SUBLIVACSUBLIVAC FIX BirchSUBLIVAC TreesSUBLIVAC FIX Mite mixture
- Other names
- Sublingual immunotherapySLIT
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Sublivac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sublivac.